Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | CASP9 | P55211 | 3/20 | 0.43 |
| ▸ | CYCS | P99999 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704927 | 0.92 | APAF1 (0.45) | APAF1CASP3CASP9CYCSSMN1; SMN2 | |
| SCHEMBL3697638 | 0.90 | APAF1 (0.44) | APAF1CASP3CASP9CYCSSMN1; SMN2 | |
| SCHEMBL3694913 | 0.89 | APAF1 (0.49) | APAF1CASP3CASP9CYCSSMN1; SMN2 | |
| SCHEMBL5956659 | 0.89 | APAF1 (0.48) | APAF1CASP3CASP9CYCSSMN1; SMN2 | |
| SCHEMBL3702024 | 0.88 | APAF1 (0.41) | APAF1CASP3CASP9CYCSSMN1; SMN2 | |
| SCHEMBL3702272 | 0.88 | CA1 (0.46) | APAF1CASP3CASP9CYCSCA1 | |
| SCHEMBL3696837 | 0.87 | KMT2A (0.44) | APAF1CASP3CASP9CYCSSMN1; SMN2 | |
| SCHEMBL3704424 | 0.86 | APAF1 (0.48) | APAF1CASP3CASP9CYCS | |
| SCHEMBL3704035 | 0.85 | CA1 (0.47) | APAF1CASP3CASP9CYCSCA1 | |
| SCHEMBL3699463 | 0.85 | APAF1 (0.50) | APAF1CASP3CASP9CYCSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| EP-2460798-A2 | APAF-1 INHIBITOR COMPOUNDS | Laboratorios SALVAT, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | APAF1 1/4885CASP3 13/4885CASP9 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.